HUMANIZED PMN310 SHOWS ENHANCED THERAPEUTIC POTENTIAL BY BINDING TOXIC LOW MOLECULAR WEIGHT Aβ OLIGOMERS WHILE AVOIDING ARIA-RELATED BINDING TO Aβ DEPOSITS IN AD PATIENT BRAINS